Qiagen N : Stifel – European Healthcare Summit Capital Markets Day Presentation

COMMITTED TO SOLID PROFITABLE GROWTH

Capital Markets Day June 17, 2024

CAPITAL MARKETS DAY MICROSITE

Webcast, presentation, infographic and additional information to be found here.

Recording available after the event.

Photos and video recordings of participants will be taken during this event. These may be used for future publications and marketing by QIAGEN, including their website and social media channels.

For on-site participants:

Be aware that sitting in the front row may result in being captured in photos or videos, primarily focused on the presenters on stage. If you prefer not to be featured in these media, please notify our colleagues at the registration desk.

June 17, 2024

Capital Markets Day 2024

2

2024 QIAGEN CAPITAL MARKETS DAY AGENDA

12:00 - 12:10	Introduction	10	John Gilardi
Vice President, Corporate Communications and Investor Relations
12:10 - 12:40	2028 strategy	30	Thierry Bernard
Chief Executive Officer
12:40 - 13:00	Sample technologies and	20	Nitin Sood
QIAcuity dPCR	Senior Vice President, Life Sciences Business Area
13:00 - 13:20	QuantiFERON TB and	20	Fernando Beils
QIAstat-Dx	Senior Vice President, Molecular Diagnostics Business Area
13:20 - 13:35	Break	15
13:35 - 13:55	QIAGEN Digital Insights	20	Jonathan Sheldon
Senior Vice President, QIAGEN Digital Insights Business Area
13:55 - 14:15	2028 targets	20	Roland Sackers
Chief Financial Officer
14:15 - 14:45	Q&A session	30

June 17, 2024

Capital Markets Day 2024

3

TODAY'S PRESENTERS

Thierry Bernard		Roland Sackers
Chief Executive Officer		Chief Financial Officer

Thierry Bernard joined QIAGEN in 2015 to lead our growing presence in molecular diagnostics. He was named Chief Executive Officer in March 2020 after serving in this role on an interim basis, and became a member of the Managing Board in 2021.

Previously, Mr. Bernard held roles of increasing responsibility during 15 years with bioMérieux SA, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. He also held senior management roles in other leading international companies. He was named in March 2023 as Chair of the AdvaMedDx Board of Directors, a U.S. industry trade association.

Mr. Bernard has earned degrees and certifications from Sciences Po, LSE, the College of Europe, Harvard Business School, Centro de Comercio Exterior de Barcelona, and has been appointed Conseiller du Commerce Extérieur by the French government.

Roland Sackers has been Chief Financial Officer at QIAGEN since 2004 and a member of the Managing Board since 2006.

He previously was an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. Since 2019, Mr. Sackers has served on the Supervisory Board of Evotec SE, a publicly listed company based in Germany, becoming Chair of the Audit Committee in 2019 and Vice Chair of the Supervisory Board in 2021. He is also a member of the Board of the industry association BIO Deutschland.

Mr. Sackers earned his Diplom-Kaufmann from the University of Münster.

June 17, 2024

Capital Markets Day 2024

4

TODAY'S PRESENTERS

Nitin Sood		Fernando Beils		Jonathan Sheldon
Senior Vice President,		Senior Vice President,		Senior Vice President,
Life Sciences		Molecular Diagnostics		QIAGEN Digital Insights

Nitin Sood joined QIAGEN in 2023 as Senior Vice President, Head of the Life Sciences Business Area, and member of the Executive Committee.

He most recently served as Chief Commercial Officer, MRD, at Adaptive Biotechnologies. He has enjoyed a 20-year career in the diagnostic and life science fields, having also held leadership roles at Guardant Health, PerkinElmer, Agilent Technologies and NuGEN Technologies.

He holds a Master's degree from Delhi University in Molecular Biology and a Master's degree from Ball State University in Computer Science.

Fernando Beils joined QIAGEN in 2023 as Senior Vice President, Head of the Molecular Diagnostics Business Area, and member of the Executive Committee.

He has worked in various global leadership roles within the diagnostics industry during his career, and most recently served as Vice President and General Manager of the Genetic Testing Solutions Business at Thermo Fisher Scientific. Prior to this role, he spent over two decades at Siemens in commercial, strategy and finance roles, and in his last role as Global Head of the Molecular Diagnostics Business Unit at Siemens Healthineers.

He earned a degree in Business Administration from EWA Madrid and the University Mosbach School of Business.

Dr. Jonathan Sheldon joined QIAGEN in 2018 as Senior Vice President, Head of the QIAGEN Digital Insights Business Area. He leads QIAGEN's growing presence in bioinformatics, enabling customers to transform raw data from biological samples into valuable molecular insights.

Dr. Sheldon came to QIAGEN from Oracle, where he was Global Vice President leading Oracle's Healthcare business globally in the Health Sciences Global Business Unit and served on the executive committee. Previously, he served as Head of Bioinformatics at Roche (UK) Pharmaceuticals, as well as in software firms serving the life science and healthcare sectors.

He received his B.Sc. in Biochemistry and Molecular Biology from the University of Manchester, and his Ph.D. in Biochemistry and Molecular Biology from the University of Cambridge.

June 17, 2024

Capital Markets Day 2024

5

Forward looking and intended use statements

Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as "believe", "hope", "plan", "intend", "seek", "may", "will", "could", "should", "would", "expect", "anticipate", "estimate", "continue", "target" or other similar words. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, adjusted diluted earnings per share results, expansion of adjusted operating income margin, returns to shareholders, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tax laws, regulatory processes and dependence on suppliers and logistics services); variability of operating results; integration of acquired businesses; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and rising interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted gross income, adjusted net income, adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted operating income margin, adjusted net income before taxes, adjusted income tax, adjusted tax rate, adjusted EBITDA, adjusted EPS, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. QIAGEN does not reconcile forward-lookingnon-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-lookingnon-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN's GAAP results.

June 17, 2024

Capital Markets Day 2024

6

Thierry Bernard

Chief Executive Officer

2028 STRATEGY

COMMITTED TO SOLID PROFITABLE GROWTH

June 17, 2024

Capital Markets Day 2024

7

THE VALUE OF BIOLOGY

HAS NEVER BEEN STRONGER

Crucialto	Improving	Direct impact
advancing	healthcare	on your
science	for all	lives

June 17, 2024

Capital Markets Day 2024

8

QIAGEN MORE FOCUSED AND STRONGER THAN EVER

QIAGEN customers

QIAGEN product groups

LIFE

MOLECULAR

~$13-14 bn

SCIENCES

DIAGNOSTICS

addressable

Sample technologies

market

ENHANCING

~4-6%

(2028)

PCR

CAGR

GROWTH

AND VALUE

Genomics / NGS

~$11 bn

addressable

Diagnostic solutions

market

(2024)

+7%	>85%	>60,000	>17,000
non-COVID sales	highly recurring	annual mentions in	new instrument
CAGR (2019-23)	revenues	academic journals	placements since 2019
CAGR - Compound annual growth rate	Total addressable market based on QIAGEN estimates

June 17, 2024

Capital Markets Day 2024

9

WELL-BALANCED ACROSS KEY MARKET DIMENSIONS

Balanced portfolio

47% Customers 53%

Molecular Diagnostics Life Sciences

2023 net sales: ~$2 bn

Diversified product base Strong recurring revenues

					12%
36%		34%
			Product		Product
			groups		types
3%		15%	88%
12%
	Sample technologies		Consumables and related revenues
	Diagnostic solutions		(including bioinformatics)

PCR / Nucleic acid amplification		Instruments
Genomics / NGS
Other

Global presence

16%

32%

Regions

52%

Americas

EMEA Asia-Pacific / Japan

June 17, 2024

Capital Markets Day 2024

10